Graves' disease, endocrine ophthalmopathy and smoking.

Acta Endocrinol (Copenh)

Department of Internal Medicine, University Hospital, Uppsala, Sweden.

Published: February 1993

We have evaluated the association between smoking, Graves' disease and endocrine ophthalmopathy in a case-control study of 208 patients with newly diagnosed Graves' disease and carried out a retrospective survey of 72 patients treated for Graves' disease and admitted to our ward because of endocrine ophthalmopathy. In the prospective study, patients with Graves' disease smoked significantly more than their healthy controls (41% vs 30%, p < 0.01 for current smokers, odds ratio 1.6, 95% confidence interval 1.1-2.3, and p < 0.05 for patients with a history of smoking, odds ratio: 1.4, 95% confidence interval 1.0-1.9). Among the patients with endocrine ophthalmopathy at diagnosis, there were slightly more patients with a history of smoking (p < 0.05, odds ratio 2.1, 95% confidence interval 1.1-3.9), but not more current smokers when compared with the remaining group. The patients with eye problems tended to have a more active disease with higher levels of thyroxine and TSH-receptor antibodies, but no difference was seen in thyrogastric autoantibodies. No effect of smoking on thyroid hormone and autoantibody levels could be detected. In the retrospective survey we found 64%, 71% and 87% smokers among patients with moderate, severe and malignant eye disease, respectively. In summary, the results show that smoking is associated with an increased risk of contracting Graves' disease and that it enhances the severity of the eye disease in cases that develop endocrine ophthalmopathy during the course of treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1530/acta.0.1280156DOI Listing

Publication Analysis

Top Keywords

graves' disease
24
endocrine ophthalmopathy
20
odds ratio
12
ratio 95%
12
95% confidence
12
confidence interval
12
disease endocrine
8
disease
8
patients
8
retrospective survey
8

Similar Publications

Graves' disease is caused by overactivation of the thyroid-stimulating hormone receptor (TSHR). One approach for its treatment may be the use of negative allosteric modulators (NAM) of TSHR, which normalize TSHR activity and do not cause thyroid hormone (TH) deficiency. The aim of the work was to study the effect of a new compound 5-amino-4-(4-bromophenyl)-2-(methylthio)thieno[2,3-d]pyrimidine-6-carboxylic acid N-tert-butylamide (TPY4) on the basal and TSH-stimulated TH production in cultured FRTL-5 thyrocytes and on basal and thyrotropin-releasing hormone (TRH)-stimulated TH levels in the blood of rats.

View Article and Find Full Text PDF

THE SERUM CREATININE TO CYSTATIN RATIO IN THYROTOXICOSIS PATIENTS: A CASE-CONTROL STUDY.

Acta Endocrinol (Buchar)

January 2025

Zigong Fourth People's Hospital, Department of Endocrinology, Zigong, Sichuan, China.

Context: Previous studies have demonstrated a correlation between creatinine and cystatin levels and thyroid disorders.

Objective: To further investigate the diagnostic value of serum creatinine to cystatin C ratio in the diagnosis of thyrotoxicosis.

Design: One hundred eighty four thyrotoxicosis patients and 406 healthy controls were enrolled.

View Article and Find Full Text PDF

Study on the correlation between serum IgG4/IgG levels and the development of Graves' ophthalmopathy.

Sci Rep

January 2025

Department of Endocrinology and Metabolism, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No.17 Yongwaizheng St, Nanchang, 330006, Jiangxi Province, People's Republic of China.

Graves' ophthalmopathy (GO) with elevated IgG4 levels has different characteristics from patients with GO who do not have elevated IgG4 levels, but the study findings are contradictory. The goal of this study was first to investigate the relationship between IgG4/IgG and IgG4 levels and the occurrence of GO and then to investigate the clinical and laboratory characteristics of patients with GO who had elevated IgG4 levels. This study control group consisted of 57 Graves' disease(GD)patients with no complicated ocular disease and a median followup of 54.

View Article and Find Full Text PDF

Background: CD4+ T lymphocytes are key immune cells involved in orbital inflammation in thyroid eye disease (TED). Inhibition of their activity is important in treatment of TED, but effective drugs targeting these cells are lacking. The programmed cell death-1/programmed cell death ligand-1 pathway has been implicated in several T-cell-mediated diseases.

View Article and Find Full Text PDF

Thyroid-Targeted Nano-Bombs Empower HIFU for Graves' Disease.

Adv Sci (Weinh)

January 2025

The Department of Head and Neck Surgery, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, 515041, P. R. China.

Graves' disease (GD) is an autoimmune disorder with a high incidence rate, particularly affecting women of reproductive age. Current treatment modalities for GD carry significant disadvantages, especially for pregnant or nursing women. As a novel extracorporeal therapeutic technique, high-intensity focused ultrasound (HIFU) shows great promise for treating GD; however, its low treatment efficacy impedes clinical application.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!